title: Simultaneous Therapy with Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema.
abstract: To investigate the safety profile and benefits of a short-term simultaneous treatment regimen combining two drugs-an intravitreal implant of dexamethasone with an intravitreal injection of bevacizumab-in patients with macular edema. This was a retrospective, non-randomized, open-label case series study. Patients were treated between April 2014 and July 2015 and were diagnosed with recurrent macular edema secondary to diabetic retinopathy and retinal vein occlusion. They underwent simultaneous treatment with an intravitreal injection of bevacizumab (1.25 mg) and an intravitreal implant of dexamethasone (0.7 mg). Patients were evaluated at baseline and at each subsequent visit with a complete ophthalmological examination and spectral-domain optical coherence tomography (OCT) scans. They were examined 24 hours after the treatment, and then followed up after 30 days and 60 days. Twenty patients (representing 20 eyes) were included in the study. At the time of injection (i.e., baseline), the best-corrected visual acuity (BCVA) was 0.758 ± 0.42 logarithm of the minimum angle of resolution (logMAR). It improved significantly to 0.51 ± 0.33 logMAR at 1 month and to 0.5 ± 0.34 logMAR at 2 months (P ≤ 0.03). The median baseline central macular thickness (CMT) was 542 µm (interquartile range, 466 - 751 µm). The median CMT decreased significantly to 321 µm (interquartile range, 288-381 µm) at 1 month and 310 µm (interquartile range, 286 - 354 µm) at 2 months (P ≤ 0.0002). The mean intraocular pressure (IOP) increased from 14.9 ± 2.29 mmHg (at baseline) to 16.5 ± 2.99 mmHg (P = 0.04) after 2 months. Two (10%) eyes showed cataract progression. There were no other ocular or systemic complications for the duration of this study. Simultaneous therapy combining a dexamethasone implant plus bevacizumab for macular edema may be an attractive treatment regimen with an acceptable safety profile.
authors.affiliation: Retina Clinic, Rua Eloi Cândido Lopes, 291 Centro, Osasco - SP, 06010-130, Brazil.
authors.forename: Felipe L
authors.initials: FL
authors.lastname: de Andrade
authors.affiliation: Retina Clinic, Rua Eloi Cândido Lopes, 291 Centro, Osasco - SP, 06010-130, Brazil.
authors.forename: Flavio S
authors.initials: FS
authors.lastname: Lopes
authors.affiliation: Retina Clinic, Rua Eloi Cândido Lopes, 291 Centro, Osasco - SP, 06010-130, Brazil.
authors.forename: Gabriel C
authors.initials: GC
authors.lastname: de Andrade
authors.affiliation: Federal University of São Paulo, Rua Sena Madureira, 1500 - Vila Mariana, São Paulo - SP, 04021-001, Brazil.
authors.forename: Tiago S
authors.initials: TS
authors.lastname: Prata
authors.affiliation: Retina Clinic, Rua Eloi Cândido Lopes, 291 Centro, Osasco - SP, 06010-130, Brazil; Federal University of São Paulo, Rua Sena Madureira, 1500 - Vila Mariana, São Paulo - SP, 04021-001, Brazil.
authors.forename: André
authors.initials: A
authors.lastname: Maia
keywords: Bevacizumab; Dexamethasone; Immunosuppression; Macular Edema; Retinal Vein Occlusion